1/18
Vocabulary practice flashcards covering fundamental clinical pharmacology concepts, including routes of administration, pharmacokinetic parameters, clearance mechanisms, receptor dynamics, and pharmacodynamic interactions based on clinical case study questions.
Sublingual Route
A route of administration providing rapid drug absorption directly across the oral mucosa into the systemic circulation, avoiding the hepatic first-pass effect, making it ideal for the immediate relief of acute angina attacks.
Transdermal Patch
A continuous, slow-release formulation applied to the skin that provides steady systemic drug delivery for long-term prophylaxis rather than rapid symptom relief during acute exertion.
Intestinal Passage and Drug Absorption
The movement and transit of an orally administered drug through the gastrointestinal tract, which can be severely disrupted following bowel obstruction, adhesions, or surgical resection, preventing adequate systemic drug absorption.
Rifampicin
An antibiotic that functions as a potent hepatic enzyme inducer, increasing the metabolic clearance of co-administered drugs such as combined oral contraceptives and resulting in contraceptive failure.
Urinary Acidification
A technique using ammonium chloride to lower urine pH, which converts weak bases (such as amphetamine) into their charged, ionized form, preventing tubular reabsorption and enhancing renal excretion.
Passive Absorption of Weak Acids
The preferential diffusion of weak acids across lipid membranes in their non-ionized, uncharged state, which is maximized in low-pH environments such as the stomach (pH∼1.5) when drug pKa is higher than ambient pH.
Renal Function Assessment
The critical pharmacokinetic evaluation required before selecting a maintenance dosing regimen for drugs primarily eliminated unchanged by the kidneys, particularly in patients with conditions like CKD stage 4.
Hepatic Clearance Impairment
A reduction in the liver's capacity to metabolize and clear drugs in the setting of severe hepatic dysfunction, leading to decreased clearance, increased systemic drug exposure, and prolonged drug half-life.
Loading Dose
An initial higher dose administered to rapidly achieve the target therapeutic steady-state plasma concentration before several elimination half-lives have elapsed, particularly valuable for drugs with long half-lives.
Zero-Order Elimination
A pharmacokinetic process where a constant amount of drug is eliminated per unit time because elimination pathways or metabolizing enzymes have become saturated at high concentrations.
Steady-State Infusion Rate (R0)
The continuous rate of IV drug delivery required to maintain a target steady-state concentration (Css), calculated as R0=CL×Css (for example, 5L/hour×8mg/L=40mg/hour).
Excretion into Breast Milk
The passive diffusion of medications into lactation fluid, favored by high lipid solubility and a weak base nature due to ion trapping in slightly acidic breast milk.
Partial Agonist
A drug that binds to a specific receptor but produces a submaximal biological response (e.g., 60% of maximal effect) even when occupying 100% of the available receptors.
Physiological Antagonism
A type of antagonism where two different agonist drugs act through independent, distinct receptor systems to produce opposing biological effects, such as epinephrine causing bronchodilation while histamine causes bronchoconstriction.
Pharmacokinetic Antagonism
An interaction where one drug reduces the effective biological concentration of another drug by accelerating its elimination, decreasing its absorption, or enhancing its hepatic metabolism.
Pharmacogenetic Abnormality
A genetically determined enzyme or receptor alteration, such as inherited pseudocholinesterase deficiency, that leads to an atypical or exaggerated response to standard drug doses (e.g., prolonged succinylcholine paralysis).
Receptor Upregulation
An increase in the total number of cell-surface receptors following prolonged exposure to a receptor antagonist, which can precipitate an exaggerated rebound response upon sudden withdrawal of the antagonist.
All-or-None Effect
The teratogenic outcome observed during the pre-differentiation phase of embryonic development (the first 17 days after conception), which results in either complete embryonic death or total survival without structural malformations.
Drug Potency
A measure of the concentration or dose of a drug required to produce a given magnitude of biological effect; a drug requiring a lower dose (e.g., 5 mg vs. 500 mg) to produce an identical response is considered more potent.